They demonstrated that inhibition of these targets could mitigate ALS pathology and prolong survival in animal models and iPSCs-MNs models from various genetic backgrounds carrying mutant C9orf72, TARDBP, and FUS, and sporadic cases of ALS. The gene discussed is TARDBP; the disease is amyotrophic lateral sclerosis.